Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial (Q37113099)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 July 2013

Language	Label	Description	Also known as
English	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial	scientific article published on 16 July 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

phase II clinical trial

0 references

stem cell transplantation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Stefanie Sarantopoulos

4

object named as

Stefanie Sarantopoulos

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

14

object named as

Bruce R Blazar

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

17

object named as

Joseph H Antin

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

16

object named as

Jerome Ritz

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Corey Cutler

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Haesook T Kim

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Bhavjot Bindra

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Vincent T Ho

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Yi-Bin Chen

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jacalyn Rosenblatt

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sean McDonough

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Phandee Watanaboonyongcharoen

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Philippe Armand

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

John Koreth

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Brett Glotzbecker

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Edwin Alyea

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Robert J Soiffer

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

16 July 2013

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

122

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1510-1517

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Advances in human B cell phenotypic profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

A disease risk index for patients undergoing allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Effector and regulatory B cells: modulators of CD4+ T cell immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

The role of B cells in the pathogenesis of graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Rituximab for steroid-refractory chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

14 September 2017

Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

27 June 2018

CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

3 September 2018

Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

3 September 2018

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

3 September 2018

Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

3 September 2018

Chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

3 September 2018

B-cell involvement in chronic graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750344

4 December 2018

Protective conditioning for acute graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab as salvage therapy for refractory chronic GVHD

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23861248

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2013-04-495895

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37113099&oldid=2154415751"